PT-141 (Bremelanotide) Molecular Structure & Chemical Properties

PT-141 represents a significant milestone in sexual dysfunction research as the first FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Originally developed from melanotan II during tanning peptide research in the 1990s, this cyclic heptapeptide unexpectedly demonstrated potent effects on sexual arousal and desire in preclinical studies. Unlike traditional phosphodiesterase-5 inhibitors that target vascular function, PT-141 acts centrally through brain melanocortin pathways, making it the first centrally-acting agent approved for sexual dysfunction. The peptide received FDA approval in June 2019 under the brand name Vyleesi for treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, establishing it as a first-in-class medication with a novel mechanism distinct from all previous sexual dysfunction treatments.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s cyclic heptapeptide structure distinguishes it from its parent compound melanotan II through the absence of a C-terminal amide group, which reduces melanogenic (skin-darkening) effects while preserving central nervous system activity on sexual function pathways.

PT-141 (Bremelanotide) Mechanism of Action

PT-141 peptide exerts its effects through activation of melanocortin receptor systems in the central nervous system, particularly within the hypothalamus. Unlike peripherally-acting sexual dysfunction medications that enhance blood flow, PT-141 modulates brain circuits involved in sexual desire and arousal, representing a fundamentally different therapeutic approach. Current evidence indicates that melanocortin-4 receptor (MC4R) activation serves as the primary driver of its sexual function effects, with additional contributions from MC3R and MC1R pathways.

Melanocortin Receptor Activation

PT-141 peptide functions as a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. Research demonstrates that therapeutic effects on sexual desire occur primarily through MC4R and MC3R agonism. These receptors are densely expressed in the hypothalamus, particularly the medial preoptic area (mPOA), a brain region critical for sexual behavior across multiple species. MC4R activation appears most relevant at therapeutic doses, with this receptor playing key roles in:

• Regulation of sexual motivation and arousal
• Integration of sensory inputs related to sexual cues
• Modulation of autonomic responses during sexual activity
• Coordination of behavioral and physiological sexual responses

Hypothalamic Pathway Modulation

Studies using c-Fos immunoreactivity mapping in rat models showed that systemic PT-141 administration activates neurons throughout the hypothalamus, including the mPOA, paraventricular nucleus, and arcuate nucleus. The mPOA represents a particularly important target, as this region integrates hormonal, sensory, and emotional inputs to regulate sexual behavior. PT-141 activation of mPOA neurons appears to initiate downstream signaling cascades that:

• Enhance processing of sexual stimuli and context
• Increase neural responsiveness to arousal cues
• Facilitate coordination of sexual behavior patterns
• Modulate autonomic and endocrine responses

Dopaminergic System Interactions

Evidence from animal studies suggests PT-141’s effects may involve modulation of dopamine signaling in brain regions controlling sexual function. While PT-141 does not directly act on dopamine receptors, melanocortin receptor activation in the hypothalamus appears to influence dopaminergic neurotransmission. Research indicates potential mechanisms including:

• Increased dopamine release in the mPOA following MC4R activation
• Enhanced dopaminergic neuron activity in reward pathways
• Modulation of dopamine receptor sensitivity in sexual behavior circuits
• Indirect effects on mesolimbic reward processing

Animal studies using microdialysis demonstrated elevated extracellular dopamine levels in the mPOA following PT-141 administration, suggesting dopamine release may mediate some behavioral effects.

Nitric Oxide System

While PT-141’s primary mechanism involves central melanocortin pathways rather than peripheral vascular systems, research indicates potential interactions with nitric oxide signaling. Unlike PDE5 inhibitors that directly enhance nitric oxide-mediated vasodilation, PT-141 peptide may influence nitric oxide systems through:

• Central nervous system nitric oxide synthase modulation
• Indirect effects on peripheral autonomic function
• Coordination of vascular responses with central arousal
• Integration with other neurotransmitter systems

PT-141 (Bremelanotide) Research Applications & Key Findings

Female Sexual Dysfunction Research

Hypoactive Sexual Desire Disorder Studies

The most extensive clinical research on PT-141 has focused on hypoactive sexual desire disorder (HSDD) in premenopausal women. Phase 2 dose-finding trials evaluated subcutaneous doses of 0.75 mg, 1.25 mg, and 1.75 mg administered as needed over 12 weeks. Results from 327 women demonstrated:

• Significant increases in satisfying sexual events compared to placebo at 1.25 mg and 1.75 mg doses
• Improved Female Sexual Function Index total scores (mean improvement of 3.6 points vs 1.9 for placebo)
• Reduced sexual distress as measured by Female Sexual Distress Scale scores
• Dose-dependent response with optimal effects at 1.75 mg

Two Phase 3 trials (RECONNECT studies) enrolled over 1,200 premenopausal women with acquired, generalized HSDD and confirmed efficacy at the 1.75 mg dose administered subcutaneously at least 45 minutes before anticipated sexual activity.

Arousal and Subjective Response Studies

An early proof-of-concept study in 18 premenopausal women with sexual arousal disorder evaluated intranasal PT-141 (20 mg) effects on physiological and subjective sexual response. Women viewed neutral and sexually explicit videos after treatment, with measurements including:

• Vaginal pulse amplitude via photoplethysmography (objective arousal measure)
• Self-reported desire and arousal ratings
• Perceived sexual response within 24 hours post-treatment

Results showed PT-141 significantly increased subjective measures of sexual desire and arousal compared to placebo, though objective physiological measures showed variable responses.

Male Sexual Dysfunction Research

Erectile Dysfunction Studies

Multiple Phase 2 trials evaluated intranasal PT-141 in men with mild-to-moderate erectile dysfunction. A double-blind, placebo-controlled trial in healthy males and ED patients tested doses ranging from 7 mg to 20 mg. Key findings included:

• Statistically significant erectile responses at doses above 7 mg compared to placebo
• Onset of first erection occurring approximately 30 minutes post-administration
• Mean duration of adequate erection rigidity increasing from 18 minutes to 73 minutes at higher doses
• Efficacy in approximately one-third of men who had inadequate response to sildenafil

Studies using subcutaneous administration (1.0-10.0 mg) in men with inadequate Viagra response demonstrated dose-dependent improvements in penile rigidity and erectile function.

Central vs Peripheral Mechanisms

Unlike PDE5 inhibitors requiring sexual stimulation and functional vascular systems, PT-141 induced erections through central mechanisms. This distinction proved relevant in animal studies where PT-141 produced:

• Penile erections in rats and non-human primates following systemic administration
• Erections after direct injection into brain ventricles, confirming central site of action
• Effects that persisted even when peripheral vascular function was compromised
• Enhanced sexual motivation behaviors distinct from purely erectile responses

Preclinical Animal Studies

Sexual Behavior in Female Rodents

Landmark research using female rats in pacing chambers demonstrated PT-141’s selective effects on appetitive sexual behaviors. Studies examining ovariectomized, hormone-primed female rats showed:

• Dramatic increases in solicitation behaviors (hopping, darting, ear-wiggling) at doses of 100-200 mcg/kg
• No effects on consummatory behaviors such as lordosis
• Selective enhancement of proceptive (desire-related) behaviors without affecting receptivity
• Effects mediated through the medial preoptic area, as direct mPOA injections replicated systemic effects

These findings established PT-141 as the first pharmacological agent demonstrating selective appetitive sexual behavior enhancement in preclinical models.

Brain Activation Studies

Neuroanatomical studies using c-Fos immunoreactivity (a marker of neuronal activation) mapped PT-141’s central effects:

• Activation concentrated in hypothalamic nuclei including mPOA, paraventricular nucleus, and arcuate nucleus
• Limbic system activation in regions processing reward and motivation
• Dose-dependent activation patterns correlating with behavioral responses
• Selective activation in regions known to control sexual function across species

PT-141 (Bremelanotide) Pharmacokinetics & Metabolism

Absorption & Distribution

PT-141 demonstrates favorable pharmacokinetic properties for on-demand use in sexual dysfunction treatment. Following subcutaneous injection in human studies:

• Bioavailability approaches 100% with subcutaneous administration
• Time to maximum plasma concentration (Tmax) occurs at approximately 1.0 hour (range 0.5-1.0 hours)
• Maximum plasma concentration (Cmax) averages 72.8 ng/mL
• Area under the curve (AUC) measures 276 hr·ng/mL

The peptide exhibits relatively low plasma protein binding at 21%, allowing substantial free drug availability for central nervous system penetration. Distribution studies indicate PT-141 crosses the blood-brain barrier effectively, consistent with its centrally-mediated mechanism of action. The rapid absorption profile supports the recommended administration timing of 45 minutes before anticipated sexual activity.

Early development included intranasal formulations showing similar rapid absorption, though these were discontinued due to blood pressure concerns. Intranasal administration achieved median Tmax of 0.50 hours with terminal half-life ranging from 1.85 to 2.09 hours in male studies.

Metabolism & Elimination

PT-141 undergoes metabolism primarily through hydrolysis of peptide bonds, a typical degradation pathway for peptide therapeutics. The relatively short plasma half-life of 2.7 hours (range 1.9-4.0 hours) reflects this enzymatic breakdown. Unlike small molecule drugs requiring hepatic cytochrome P450 metabolism, PT-141’s peptide structure results in:

• Breakdown into constituent amino acids through peptidase activity
• No significant cytochrome P450 enzyme interactions
• Minimal potential for drug-drug interactions through metabolic pathways
• No active metabolites requiring consideration for efficacy or safety

The peptide’s metabolic profile contributes to its favorable safety regarding drug interactions, with no clinically significant interactions identified with alcohol or common medications.

Excretion Pathways

Radiolabeled studies in humans established PT-141’s elimination pathways:

• 64.8% of administered dose recovered in urine
• 22.8% of dose recovered in feces
• Complete elimination occurring within several days
• No evidence of accumulation with repeated administration

The predominantly renal excretion pattern and absence of accumulation support the approved dosing regimen of no more than one dose per 24 hours and maximum eight doses per month. Despite the relatively short half-life, clinical effects can persist for several hours to days after administration, suggesting that pharmacodynamic effects outlast plasma drug levels through persistent changes in neural circuit activity initiated by melanocortin receptor activation.

PT-141 (Bremelanotide) Research Protocols & Administration

Dosing in Published Research

Research investigations have established different dosing ranges across preclinical and clinical studies:

Animal Studies:

• Rat models: 100-200 mcg/kg for female sexual behavior studies; 50-500 mcg/kg for male erectile function
• Non-human primates: 50 mcg/kg demonstrated erectogenic effects

Human Clinical Trials:

• Intranasal formulation (discontinued): 7-20 mg in male ED studies; 20 mg in female arousal studies
• Subcutaneous injection: 0.75 mg, 1.25 mg, and 1.75 mg in Phase 2-3 female HSDD trials
• FDA-approved dose: 1.75 mg subcutaneously as needed, at least 45 minutes before sexual activity

Important: These are doses from completed clinical trials. Animal study doses cannot be extrapolated to other species due to profound differences in melanocortin receptor expression, distribution, pharmacokinetics, metabolic rates, and species-specific neural circuit organization. Cross-species dose conversion requires extensive pharmacokinetic and pharmacodynamic studies beyond simple body weight or surface area calculations.

Administration Routes in Research

Multiple delivery methods have been investigated throughout PT-141’s development:

• Subcutaneous injection – Current FDA-approved route; administered via single-dose autoinjector to abdomen or thigh
• Intranasal administration – Studied extensively in Phase 2 trials but discontinued due to blood pressure elevations; faster onset but less predictable absorption
• Intravenous injection – Used only in pharmacokinetic characterization studies; not practical for on-demand use
• Direct brain injection – Employed in animal mechanistic studies to confirm central site of action; lateral ventricle and medial preoptic area injections demonstrated local effects

The subcutaneous route ultimately proved most suitable for clinical development, offering reliable absorption, manageable side effects, and practical at-home self-administration.

Common Model Organisms

PT-141 research has utilized multiple species to establish mechanism and efficacy:

• Rats – Primary model for sexual behavior studies (Sprague-Dawley, Long-Evans strains); extensive data on female solicitation behaviors and male erectile responses
• Mice – Used for genetic receptor studies and neuroanatomical mapping
• Non-human primates – Demonstrated penile erections following systemic administration; important for validating cross-species effects
• Humans – Multiple Phase 1-3 trials in healthy volunteers and patients with sexual dysfunction
• Cell culture – MC4R-expressing cell lines for receptor binding and signaling studies

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite FDA approval for a specific indication and extensive research over two decades, PT-141 faces several important limitations that restrict broader clinical application and understanding.

Limited Scope of FDA Approval

The most significant limitation is the narrow approved indication:

• FDA approval restricted exclusively to acquired, generalized hypoactive sexual desire disorder in premenopausal women
• No approved indication for men despite Phase 2 evidence of erectile dysfunction improvement
• No approval for postmenopausal women
• No approval for other forms of sexual dysfunction beyond HSDD

All use outside this single indication represents off-label prescribing based on limited clinical trial data and physician clinical experience.

Mechanistic Understanding Gaps

Fundamental aspects of PT-141’s mechanism remain incompletely characterized:

• Precise molecular pathways linking MC4R activation to behavioral changes undefined
• Relative contributions of different melanocortin receptor subtypes unclear
• Role of downstream neurotransmitter systems (dopamine, norepinephrine, serotonin) incompletely mapped
• Why effects on sexual desire persist beyond drug elimination half-life remains unexplained
• Individual variation in response not well predicted by current biomarkers

Long-Term Safety and Efficacy Data

Critical safety questions remain inadequately addressed:

• Chronic use effects beyond one year unstudied in controlled trials
• Long-term cardiovascular safety requires extended monitoring given transient blood pressure effects
• Persistent hyperpigmentation risk with frequent use not fully characterized
• Developmental and reproductive toxicity data limited
• Effects on fertility and pregnancy outcomes require further study

The longest controlled trial duration was 52 weeks, leaving questions about multi-year safety unanswered.

Regulatory & Competitive Sport Status

FDA Position

PT-141 received FDA approval in June 2019 but with significant restrictions:

• Approved as Vyleesi (bremelanotide injection) for one specific indication only
• Contraindicated in patients with uncontrolled hypertension or cardiovascular disease due to transient blood pressure effects
• Prescribing guidelines limit use to maximum one dose per 24 hours and eight doses per month
• Discontinuation recommended after 8 weeks if no improvement observed
• No approved use in men despite off-label prescribing by some physicians

The FDA designation as a “first-in-class” medication reflects its novel mechanism but also indicates limited clinical experience compared to established drug classes.

WADA Prohibition Status

PT-141 is not currently listed on the World Anti-Doping Agency (WADA) Prohibited List as of 2025. However, several considerations apply:

• Melanocortin receptor agonists could theoretically fall under prohibited substance categories if evidence of performance enhancement emerged
• Athletes should consult with sports medicine physicians and anti-doping officials before use
• Lack of current prohibition does not indicate WADA endorsement or recommendation
• Future regulatory status could change based on emerging evidence

Availability and Compounding Considerations

• FDA-approved Vyleesi available only by prescription through licensed pharmacies
• Some compounding pharmacies offer PT-141, though quality, purity, and dosing accuracy may vary
• Research-grade PT-141 available from peptide suppliers for laboratory use only
• International regulatory status varies by country

Research Classification: PT-141 is available in FDA-approved form (Vyleesi) for one specific medical indication by prescription only. Research-grade material is intended exclusively for laboratory research use. It is not intended for non-medical human consumption, athletic performance enhancement, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Molinoff, P.B., Shadiack, A.M., Earle, D., Diamond, L.E., & Quon, C.Y. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96-102. PubMed
   
2. Pfaus, J.G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences USA, 101(27), 10201-10204. PubMed
   
3. Diamond, L.E., Earle, D.C., Heiman, J.R., Rosen, R.C., Perelman, M.A., & Harning, R. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine, 3(4), 628-638. PubMed
   
4. Pfaus, J., Giuliano, F., & Gelez, H. (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine, 4(Suppl 4), 269-279. PubMed
   
5. Shadiack, A.M., Sharma, S.D., Earle, D.C., Spana, C., & Hallam, T.J. (2007). Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry, 7(11), 1137-1144. PubMed
   
6. Diamond, L.E., Earle, D.C., Rosen, R.C., Willett, M.S., & Molinoff, P.B. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51-59. PubMed
   
7. Rosen, R.C., Diamond, L.E., Earle, D.C., Shadiack, A.M., & Molinoff, P.B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16(2), 135-142. PubMed
   
8. Clayton, A.H., Althof, S.E., Kingsberg, S., DeRogatis, L.R., Kroll, R., Goldstein, I., Kaminetsky, J., Spana, C., Lucas, J., Jordan, R., & Portman, D.J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health, 12(3), 325-337. PubMed
   
9. Clayton, A.H., Kingsberg, S.A., Goldstein, I., Baskin, L., Kim, N.N., Volkmann, E.R., Simon, J.A., Higgins, K.S., Jordan, R., & Portman, D.J. (2016). Evaluation of bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized Phase 3 trials. Obstetrics and Gynecology, 128(6), 1377-1385. PubMed
   
10. Clayton, A.H., Lucas, J., DeRogatis, L.R., Jordan, R., Spana, C., Aslaksen, E., & Portman, D.J. (2017). Phase 1 randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants. Journal of Clinical Pharmacology, 57(6), 764-772. PubMed
    
11. Kingsberg, S.A., Clayton, A.H., Portman, D., Williams, L.A., Krop, J., Jordan, R., Lucas, J., & Simon, J.A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized Phase 3 trials. Obstetrics and Gynecology, 134(5), 899-908. PubMed
    
12. Burrows, L.J., Goldstein, A.T., & Goldstein, I. (2021). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. Expert Review of Clinical Pharmacology, 14(2), 147-157. PubMed
    
13. White, W.B., Myers, M.G., Jordan, R., & Lucas, J. (2017). Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Journal of Hypertension, 35(4), 761-768. PubMed
    
14. Simon, J.A., Kingsberg, S.A., Portman, D.J., Lucas, J., Jordan, R., Clayton, A.H., & Shifren, J.L. (2019). Long-term safety of bremelanotide for hypoactive sexual desire disorder in premenopausal women: findings from a 52-week open-label study. Women’s Health, 15, 1-11. PubMed
    
15. U.S. Food and Drug Administration. (2019). FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. FDA News Release, June 21, 2019.

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. PT-141 (Bremelanotide) is intended for laboratory research use only.